Stay updated on Cabozantib in RET+ NSCLC: Phase II Clinical Trial

Sign up to get notified when there's something new on the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    The page revision updated the version from v3.6.5 to v3.6.6, signaling a minor update to the record. No substantive changes to the study details are indicated.
    Difference
    0.0%
    Check dated 2026-08-29T18:29:08.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    24 days ago
    No Change Detected
  5. Check
    32 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.6.5, replacing the previous v3.6.4, indicating a small update to the page template or content management system.
    Difference
    0.0%
    Check dated 2026-08-08T09:37:19.000Z thumbnail image
  6. Check
    46 days ago
    Change Detected
    Summary
    The page revision was updated to v3.6.4, replacing the previous v3.6.3. This indicates a maintenance update to the page rather than a change to study data or functionality.
    Difference
    0.0%
    Check dated 2026-07-25T06:22:42.000Z thumbnail image
  7. Check
    67 days ago
    Change Detected
    Summary
    The page's Revision tag has been updated to v3.6.3, replacing the previous v3.6.2. This indicates a minor maintenance update to the site version tag.
    Difference
    0.0%
    Check dated 2026-07-03T22:03:20.000Z thumbnail image
  8. Check
    74 days ago
    Change Detected
    Summary
    The revision line on the page was updated from Revision: v3.6.0 to Revision: v3.6.2. This indicates a newer version of the page content.
    Difference
    0.0%
    Check dated 2026-06-27T02:04:37.000Z thumbnail image
  9. Check
    81 days ago
    Change Detected
    Summary
    Removed sponsor/investigator identifiers and a drug description line, along with the attribution note, diminishing attribution and navigational context on the study's details page.
    Difference
    0.2%
    Check dated 2026-06-19T21:38:45.000Z thumbnail image

Stay in the know with updates to Cabozantib in RET+ NSCLC: Phase II Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page.